Name: National EBS Association (NEBSA) 2014 Annual Meeting
Start: 2014-02-17T05:00

Why Fish

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Pricing

Legal Project Management

Knowledge Management

eDiscovery

Legal Technology Services

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Appellate

Chancery & Corporate Governance

Post-Grant

Inter Partes Review

Post-Grant Review

Ex Parte Reexamination

Supplemental Examination

Patent

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Industries

Electrical & Computer Technology

Artificial Intelligence

Digital Health

Digital Media & E-Commerce

Financial, Business & FinTech Services

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Post-Grant Annual Reports

Hosts

Name

Ed Lavergne

Person title

Senior Principal

Principal Edwin Lavergne (DC) will present at the NEBSA 2014 Annual Meeting.

National EBS Association (NEBSA) 2014 Annual Meeting

Hosts

World IP Forum Dubai 2025

International Intellectual Property Law Association 2025 Dubai

BAAAGC X NAPABA Celebration of 200 Bay Area Asian American General Counsel

Hatch-Waxman 201

How a Second Trump Presidency Could Shape IP

Duty of Disclosure and Consistency Requirements for Statements to PTO and Other Government Agencies

Hatch-Waxman 101

Biologics and Biosimilars Landscape: IP, Policy, and Market Developments

Hatch-Waxman 2023 Year in Review

Legal Alert: Biden Administration Proposes March-In Rights Framework for Pharmaceutical Patents in Effort to Lower Drug Prices

Legal Alert: FTC Challenges More Than 100 Patents as Improperly Listed in Orange Book

Senior Principal Terry Mahn Authors Medical Device + Diagnostic Industry Article "This Company's False Compliance With CISPR 11 Resulted in a $12 Million FCA...

Biosimilars 2022 Year in Review